Back to top
more

Innoviva (INVA)

(Real Time Quote from BATS)

$20.20 USD

20.20
43,333

+0.02 (0.10%)

Updated Nov 11, 2024 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Innoviva (INVA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Innoviva (INVA) closed the most recent trading day at $14.05, moving -0.07% from the previous trading session.

Kinjel Shah headshot

5 Beaten-Down Biotech Stocks Set to Rebound in 2020

by Kinjel Shah

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

Should Value Investors Buy Innoviva (INVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis

by Zacks Equity Research

Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.

Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote

by Zacks Equity Research

Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.

BioCryst Submits NDA for Hereditary Angioedema Candidate

by Zacks Equity Research

BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.

VistaGen Up on Fast Track Designation for Anxiety Disorder Drug

by Zacks Equity Research

The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.

TG Therapeutics' Shares Soar on Positive Early-Stage Data

by Zacks Equity Research

TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.

Top Ranked Value Stocks to Buy for December 10th

by Zacks Equity Research

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 10th.

Regeneron Reports Initial Data for Multiple Myeloma Drug

by Zacks Equity Research

Regeneron (REGN) reports initial data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.

Top Ranked Value Stocks to Buy for December 9th

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 9th

Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

by Zacks Equity Research

Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.

Top Ranked Value Stocks to Buy for December 3rd

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 3rd

Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps

by Zacks Equity Research

Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.

Alexion Gets Approval for Label Expansion of Soliris in Japan

by Zacks Equity Research

Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.

Surging Earnings Estimates Signal Upside for Innoviva (INVA) Stock

by Zacks Equity Research

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Sanghamitra Saha headshot

Value ETFs & Stocks Offering Real Value: 5 Top Picks

by Sanghamitra Saha

A favorable operating backdrop and cheap valuation are leading value stocks higher. Play the trend with these cheap value stocks and ETFs.

Moleculin Files New Patents for Cancer Candidate Annamycin

by Zacks Equity Research

Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

Celgene (CELG) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

Swarup Gupta headshot

5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon

by Swarup Gupta

Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.

Earnings Estimates Moving Higher for Innoviva (INVA): Time to Buy?

by Zacks Equity Research

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for May 15th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (INVA) Outperforming Other Medical Stocks This Year?

3 Reasons Momentum Stock Investors Will Love Innoviva (INVA)

by Zacks Equity Research

Innoviva (INVA) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.